

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee April 2023 Meeting Outcome**

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Alpelisib / Fulvestrant	Piqray	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
3	Brolucizumab	Beovu	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
4	Burosumab	Crysvita	Endocrine system	Approved	
5	Busulfan	Busulfex	Malignant disease and immunosuppression	Approved	
6	Capmatinib	Tabrecta	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
7	Daratumumab / Bortezomib	Darzalex	Malignant disease and immunosuppression	Approved	
8	Dupilumab	Dupixent	Ear, nose, and oropharynx	Pending	Pending further information
9	Empagliflozin	Jardiance	Endocrine system	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
10	Esketamine	Spravato	Central nervous system	Approved	
11	Faricimab	Vabysmo	Eye	Pending	Pending further information
12	Finerenone	Kerendia	Cardiovascular system	Pending	Pending further information
13	Isatuximab / Pomalidomide	Sarclisa	Malignant disease and immunosuppression	Approved	
14	L-arginine hydrochloride / L-lysine hydrochloride	LysaKare	Nutrition and blood	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
15	Latanoprostene Bunod	Vyzulta	Eye	Approved	
16	Lutetium oxodotreotide	Lutathera	Radiopharmaceuticals	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
17	Mepolizumab	Nucala	Malignant disease and immunosuppression	Approved	
18	Nivolumab	Opdivo	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits

	<b>Generic name</b>	<b>Brand name</b>	<b>Therapeutic Class</b>	<b>Meeting outcome</b>	<b>Primary reason for rejection<sup>1</sup></b>
19	Nonacog alfa	BeneFIX	Cardiovascular system	Approved	
20	Olaparib / Bevacizumab	Lynparza	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
21	Onasemnogene abeparvovec	Zolgensma	Musculoskeletal and joint disease	Pending	Pending further information
22	Osimertinib	Tagrisso	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
23	Oxycodone / Naloxone	Targin	Central nervous system	Pending	Pending further information
24	Polatuzumab vedotin / Rituximab	Polivy	Malignant disease and immunosuppression	Approved	
25	Ravulizumab	Ultomiris	Nutrition and blood	Approved	
26	Ripretinib	Qinlock	Malignant disease and immunosuppression	Pending	Pending further information
27	Ruxolitinib	Jakavi	Malignant disease and immunosuppression	Pending	Pending further information
28	Siltuximab	Sylvant	Malignant disease and immunosuppression	Approved	
29	Tolvaptan	Jinarc	Endocrine system	Approved	
30	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Pending	Pending further information
31	Trifluridine/tipiracil	Lonsurf	Malignant disease and immunosuppression	Approved	
32	Tucatinib / Trastuzumab	Tukysa	Malignant disease and immunosuppression	Pending	Pending further information
33	Upadacitinib	Rinvoq	Skin	Approved	

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.